Personalized Glucose Targets: Adjusting Your Goals with Cgm Insights

by

Continuous Glucose Monitoring (CGM) devices have revolutionized diabetes management by providing real-time, dynamic data about blood sugar levels throughout the day and night. Unlike traditional fingerstick testing that offers only snapshots of glucose at specific moments, CGM enables patients to understand how specific foods, exercise, and stress affect glucose patterns, and adjust their lifestyle accordingly. This comprehensive approach to glucose monitoring empowers individuals to set and achieve personalized glucose targets that align with their unique health needs, lifestyle factors, and treatment goals.

The ability to personalize glucose targets represents a fundamental shift in diabetes care. Rather than applying one-size-fits-all recommendations, healthcare providers and patients can now collaborate to establish individualized goals based on continuous data streams that reveal patterns, trends, and opportunities for optimization. This article explores how to leverage CGM insights to adjust your glucose targets effectively, understand the key metrics that matter, and implement strategies for achieving better glycemic control while maintaining quality of life.

Understanding Personalized Glucose Targets in the CGM Era

Personalized glucose targets are specific blood sugar ranges tailored to an individual’s unique circumstances, including age, diabetes type, duration of disease, presence of complications, hypoglycemia awareness, and personal preferences. As medicine leans towards personalized care, doctors will be able to adjust treatments based on real patterns, not just averages. Patients can see clearly how food, exercise and sleep affect their blood sugar levels, enabling more informed decision-making about daily management strategies.

The traditional approach to diabetes management relied heavily on hemoglobin A1C measurements, which provide an average of blood glucose levels over the previous two to three months. While A1C remains an important metric, A1C measures your average glucose over the past eight to 12 weeks. An A1C test can’t give you information on blood sugar fluctuations. This limitation means that two people with identical A1C values might have vastly different glucose patterns—one experiencing dangerous highs and lows throughout the day, while another maintains relatively stable levels.

CGM technology addresses these limitations by providing continuous data that reveals the complete picture of glucose control. Continuous glucose monitoring (CGM) has significantly advanced diabetes management, evolving from early glucose testing methods to modern, FDA‐approved systems. Modern CGM devices measure glucose levels in the interstitial fluid every few minutes, creating a comprehensive record of glucose patterns that can be analyzed to identify trends, problem areas, and opportunities for improvement.

The Science Behind Time in Range

Time in range is the amount of time you spend in the target blood glucose (blood sugar) range—between 70 and 180 mg/dL for most people. This metric has emerged as a crucial complement to A1C testing, providing actionable insights that can guide daily diabetes management decisions. Time in range (TIR) represents a more nuanced understanding of glycemic control than A1C alone can provide.

For most people with type 1 or type 2 diabetes, a TIR above 70% is recommended. That’s about 17 hours of a 24-hour day. This target corresponds to an A1C of approximately 7%, but provides much more detailed information about how glucose levels fluctuate throughout the day. The beauty of TIR is that it captures not just the average, but the variability and distribution of glucose values.

Research has demonstrated the clinical significance of time in range as a predictor of diabetes complications. The more time you spend in range, the less likely you are to develop certain diabetes complications. Studies have shown associations between higher TIR and reduced risk of retinopathy, nephropathy, and cardiovascular complications, making it a valuable target for long-term health outcomes.

Understanding Time Above and Below Range

In addition to time in range, CGM data provides information about time spent above range (TAR) and time below range (TBR). You should aim to spend less than 4% (58 minutes) below 70 mg/dL, less than 1% (14 minutes) below 54 mg/dL, less than 25% (6 hours) above 180 mg/dL. These targets help ensure that efforts to improve time in range don’t inadvertently increase the risk of hypoglycemia or allow extended periods of hyperglycemia.

The standard CGM ranges are typically displayed as color-coded zones:

  • Very Low (Below 54 mg/dL): Clinically significant hypoglycemia requiring immediate attention
  • Low (54-69 mg/dL): Hypoglycemia that signals risk and requires intervention
  • In Range (70-180 mg/dL): Target glucose range for most individuals
  • High (181-250 mg/dL): Elevated glucose requiring attention
  • Very High (Above 250 mg/dL): Significant hyperglycemia requiring immediate action

Software programs for CGMs most often present time in range information as a color-coded vertical bar. The bar will show the percentage of time you’re in various ranges. The in-range section is typically green, and other ranges may be different shades of yellow, orange or red.

Using CGM Data to Adjust Your Glucose Goals

CGM devices track glucose levels continuously, providing a wealth of data that can be analyzed to identify patterns and make informed adjustments to glucose targets. CGM has demonstrated substantial improvements in glycemic control across multiple metrics. Studies report consistent glycosylated hemoglobin reductions of 0.25%–3.0% and notable time in range improvements of 15%–34%. These improvements stem from the ability to see glucose patterns in real-time and make timely adjustments to treatment strategies.

Interpreting the Ambulatory Glucose Profile

The Ambulatory Glucose Profile (AGP) is a standardized report that presents CGM data in an easy-to-understand format. At the return visit, the CGM device was removed, data were uploaded, and the patient was given a copy of the ambulatory glucose profile report. The following CGM parameters were recorded: time in range, time above range, time below range, mean glucose, glucose management indicator, and coefficient of variation.

The AGP report typically includes several key components that help guide treatment decisions:

  • Glucose Statistics: Average glucose, glucose management indicator (GMI), coefficient of variation
  • Time in Ranges: Percentage of time in target, above, and below range
  • Daily Glucose Profile: Visual representation showing median glucose and variability throughout the day
  • Daily Glucose Patterns: Identification of consistent patterns at specific times

Ambulatory Glucose Profile – AGP displays the key CGM metrics, including proportions of glucose values in different ranges over a specified time period, the recommended target for each CGM data range, and a visual demonstration of the CGM values distribution according to the time of day. This standardized presentation facilitates communication between patients and healthcare providers, making it easier to identify areas for improvement and track progress over time.

Analyzing Glucose Variability

Glucose variability (GV) is another important metric that CGM data reveals. High glucose variability—characterized by frequent swings between high and low values—can be just as problematic as poor average control. The coefficient of variation (CV) is the standard measure of glucose variability, calculated by dividing the standard deviation by the mean glucose and expressing it as a percentage.

A CV of 36% or less is generally considered the target for stable glucose control. Higher CV values indicate greater variability, which may increase the risk of both hypoglycemia and hyperglycemia. GMI and TIR can provide complementary insights into glycaemic patterns. Discordance between TIR and GMI should prompt further exploration of the GV and TBR values. When time in range appears adequate but glucose variability is high, it may indicate a need to adjust treatment strategies to achieve more stable control.

Identifying Pattern-Based Opportunities

One of the most powerful applications of CGM data is the ability to identify consistent patterns that occur at specific times of day or in response to particular activities. This collaborative approach not only encourages more efficient diabetes management but also empowers patients with a better understanding of their personalized glycemic trends and the impact of therapeutic adjustments.

Common patterns that CGM data can reveal include:

  • Dawn Phenomenon: Rising glucose levels in the early morning hours before waking
  • Postprandial Spikes: Excessive glucose elevation after meals
  • Nocturnal Hypoglycemia: Low glucose levels during sleep that may go undetected
  • Exercise-Related Fluctuations: Glucose changes during and after physical activity
  • Stress-Induced Hyperglycemia: Elevated glucose in response to emotional or physical stress

Standardized interventions regarding diet, exercise, and stress were carried out to examine individual glucose responses with corresponding kinetic metrics in healthy, young people which can serve as reference of CGM glucose profiles for future studies, while providing valuable insights into personalized glucose management. We used kinetic-mathematical metrics to describe individual glucose responses to specific stimuli.

Critical Factors to Consider When Setting Personalized Goals

While the standard time in range target of 70% (70-180 mg/dL) applies to most adults with diabetes, individual circumstances may warrant different targets. These targets should be individualized: the personal use of CGM with the standardized data presentation provides all necessary means to accurately tailor diabetes management to the needs of each individual with diabetes. Several key factors should be considered when establishing personalized glucose targets.

Age and Life Stage Considerations

Age significantly influences appropriate glucose targets. TIR targets can be lower for older or high-risk individuals and for those younger than age 25. Younger individuals, particularly children and adolescents, may require less stringent targets to minimize the risk of hypoglycemia, which can be particularly dangerous during periods of rapid growth and development. The developing brain is especially vulnerable to severe hypoglycemia, making it crucial to balance the benefits of tight control with the risks of low blood sugar.

For older adults, particularly those with multiple comorbidities, frailty, or limited life expectancy, less stringent targets may be appropriate. Older individuals may have reduced awareness of hypoglycemia symptoms, slower reaction times to treat low blood sugar, and greater risk of falls and injuries related to hypoglycemia. Additionally, the benefits of intensive glucose control may take years to manifest, making aggressive targets less appropriate for those with limited life expectancy.

Pregnant women with diabetes have unique glucose targets that are more stringent than those for non-pregnant adults. During pregnancy, tighter glucose control is necessary to minimize risks to both mother and baby, but these targets must be achieved while carefully avoiding hypoglycemia.

Diabetes Type and Duration

The type of diabetes and how long someone has had the condition influence appropriate glucose targets. Continuous glucose monitoring (CGM) has revolutionized diabetes management, significantly enhancing glycemic control across diverse patient populations. Recent evidence supports its effectiveness in both type 1 and type 2 diabetes management.

People with type 1 diabetes typically require more intensive monitoring and tighter glucose control, as they have no endogenous insulin production. They may benefit from more aggressive time in range targets and closer attention to glucose variability. However, those with long-standing type 1 diabetes and impaired hypoglycemia awareness may need less stringent targets to minimize the risk of severe hypoglycemia.

For type 2 diabetes, glucose targets may vary based on treatment regimen. People with type 1 diabetes and those with type 2 who use insulin and have tight blood glucose goals will benefit the most from reviewing their time in range data. That’s because they’re most likely to have blood glucose levels outside their target range. Those managed with lifestyle modifications alone or oral medications may have different targets than those using insulin therapy.

Presence of Complications and Comorbidities

Existing diabetes complications significantly influence appropriate glucose targets. Individuals with advanced complications such as severe cardiovascular disease, advanced kidney disease, or proliferative retinopathy may benefit from less aggressive targets to minimize the risk of acute metabolic decompensation or hypoglycemia-related adverse events.

Conversely, those without complications who are early in their diabetes course may benefit from more aggressive targets to prevent or delay the development of complications. TIR and hyperglycemia metrics are strongly associated with albuminuria in T2D. The prevalence of albuminuria was low in T2D patients who attained the required targets of TIR 70–180 mg/dL, time above range (TAR) > 180 mg/dL, and TAR >250 mg/dL. The study reported the odds of the occurrence of albuminuria as 0.94 with a10% increase in TIR.

Comorbid conditions also play a role in target setting. Individuals with conditions that increase the risk or consequences of hypoglycemia—such as coronary artery disease, arrhythmias, or seizure disorders—may require less stringent targets with particular emphasis on minimizing time below range.

Hypoglycemia Awareness and Risk

Hypoglycemia awareness—the ability to recognize symptoms of low blood sugar—is a critical factor in setting glucose targets. CGM is especially valuable for patients at increased risk of hypoglycemia, providing continuous monitoring and predictive alerts as an essential safety net. Individuals with impaired awareness of hypoglycemia are at significantly higher risk of severe hypoglycemic events and may require less stringent targets with a primary focus on avoiding time below range.

CGM technology is particularly valuable for these individuals, as it can provide alerts when glucose levels are falling or approaching the hypoglycemic range, even when the person doesn’t feel symptoms. The predictive alert features of modern CGM systems can warn users 20-30 minutes before glucose reaches a critical low, providing time to take preventive action.

Risk factors for severe hypoglycemia that should influence target setting include:

  • History of severe hypoglycemic events requiring assistance
  • Impaired hypoglycemia awareness
  • Long duration of diabetes (particularly type 1)
  • Aggressive insulin regimens
  • Irregular meal patterns or unpredictable physical activity
  • Alcohol consumption
  • Renal impairment
  • Living alone or lacking support systems

Activity Level and Lifestyle Factors

Physical activity patterns significantly influence glucose dynamics and should be considered when setting targets. A high carbohydrate load led to highest cmax and long glucose peak. During anaerobic training, glucose levels increased, whereas glucose levels remained relatively steady during aerobic training. The induction of stress caused glucose to rise significantly compared to a control setting.

Athletes and highly active individuals may experience different glucose patterns than sedentary individuals. Exercise can cause glucose levels to rise (particularly with high-intensity or anaerobic exercise) or fall (especially with prolonged moderate-intensity aerobic exercise). Understanding these patterns through CGM data allows for more precise target setting and management strategies around physical activity.

Occupation and daily routine also matter. Individuals with jobs that involve operating heavy machinery, working at heights, or requiring sustained attention may need to prioritize avoiding hypoglycemia over achieving the tightest possible control. Shift workers may experience different glucose patterns during day versus night shifts, requiring flexible target setting.

Personal Preferences and Quality of Life

Individual preferences regarding the intensity of diabetes management and tolerance for glucose fluctuations should be respected when setting targets. Some individuals prefer aggressive management and are willing to accept more frequent monitoring and intervention, while others prioritize simplicity and flexibility even if it means less optimal control.

Participants using CGM also reported higher satisfaction with their health, better diabetes-related well-being, and more positive health behaviors. It can be speculated that CGM offers personalized insights and immediate decision-making feedback on glucose trends, which may have contributed to the observed positive behavioral changes. The psychological impact of diabetes management should not be underestimated—overly aggressive targets that lead to diabetes distress or burnout may ultimately be counterproductive.

Shared decision-making between patients and healthcare providers is essential. Targets should be established collaboratively, with clear discussion of the benefits and risks of different approaches, and should be revisited regularly as circumstances change.

Practical Strategies for Achieving Your Personalized Targets

Once personalized glucose targets have been established based on individual factors, the next step is implementing strategies to achieve those targets. CGM data provides the foundation for making informed adjustments to diabetes management.

Optimizing Medication Regimens

CGM data can guide adjustments to medication timing, dosing, and selection. The CDCES or PharmD reviewed CGM data with patients and collaborated with PCPs to adjust the care plan, informed by the systematic stepwise approach to CGM interpretation. This collaborative approach ensures that medication adjustments are based on comprehensive data rather than isolated glucose readings.

For individuals using insulin, CGM data can reveal whether basal insulin doses are appropriate (by examining overnight and fasting glucose patterns), whether bolus insulin doses and timing are optimal (by analyzing postprandial glucose excursions), and whether insulin-to-carbohydrate ratios need adjustment. The ability to see glucose trends in real-time allows for more precise insulin dosing decisions.

For those using non-insulin medications, CGM data can help assess medication effectiveness and guide decisions about adding, changing, or intensifying therapy. Patients with higher baseline HbA1c levels show greater improvements with CGM use. A study involving non-insulin-treated patients with T2D uncontrolled with oral antidiabetic drugs (baseline HbA1c 8.2%±0.5%) reported significant HbA1c reductions after CGM use. This suggests that CGM may be beneficial for patients struggling to meet glycemic targets with conventional monitoring approaches.

Refining Nutrition Strategies

CGM provides immediate feedback on how different foods and eating patterns affect glucose levels, enabling more precise nutritional management. This realtime education is more impactful than traditional diabetes education methods, as it provides personalized insights specific to each individual’s unique physiological responses.

By reviewing CGM data in conjunction with food logs, individuals can identify:

  • Foods that cause excessive glucose spikes
  • Optimal timing of meals and snacks
  • Appropriate portion sizes for different foods
  • Effects of food combinations (protein, fat, and fiber with carbohydrates)
  • Impact of meal timing on overnight glucose control

This personalized nutritional information is far more valuable than generic dietary advice, as individual responses to foods can vary significantly. What causes a large glucose spike in one person may have minimal impact in another, making personalized data essential for optimal nutrition planning.

Tailoring Exercise Recommendations

Physical activity is a cornerstone of diabetes management, but its effects on glucose can be complex and variable. Exercise-induced glycemic fluctuations are particularly interesting. Participants spent about 10.3% of exercise time with glucose levels above 140 mg/dL and about 11.9% of the time below 70 mg/dL, indicating the body’s dynamic glycemic adaptation to physical effort.

CGM data can help individuals understand:

  • How different types of exercise affect glucose (aerobic vs. anaerobic, intensity levels)
  • Optimal timing of exercise relative to meals and medication
  • Whether pre-exercise snacks are needed to prevent hypoglycemia
  • How long after exercise glucose levels remain affected
  • Strategies to prevent post-exercise hypoglycemia (which can occur hours after activity)

Armed with this information, individuals can develop personalized exercise strategies that maximize the benefits of physical activity while minimizing glucose disruptions. This might include adjusting insulin doses before exercise, consuming specific amounts of carbohydrates at particular times, or choosing certain types of exercise based on current glucose levels and trends.

Managing Stress and Sleep

CGM data can reveal the often-underappreciated effects of stress and sleep on glucose control. Psychological stress triggers the release of counter-regulatory hormones like cortisol and adrenaline, which can raise glucose levels. Poor sleep quality or insufficient sleep can impair insulin sensitivity and glucose regulation.

CGMs have also been successful in identifying blood sugar swings for people with sleep apnea and gastroparesis. By examining overnight glucose patterns, individuals can assess sleep quality’s impact on glucose control and identify issues like sleep apnea that may be contributing to poor glycemic control.

Strategies for managing stress and sleep-related glucose fluctuations include:

  • Stress reduction techniques (meditation, yoga, deep breathing)
  • Improving sleep hygiene
  • Treating underlying sleep disorders
  • Adjusting medication timing to address stress-related patterns
  • Planning for predictable stressful events (work deadlines, travel)

Advanced CGM Metrics and Emerging Concepts

As CGM technology continues to evolve, new metrics and concepts are emerging that provide even more detailed insights into glucose control and help refine personalized targets.

Time in Tight Range

While the standard time in range target is 70-180 mg/dL, some research has explored the concept of “time in tight range” (TITR), typically defined as 70-140 mg/dL. The consensus defined the concept of the time spent in the target range, or simply “time in range” and standardizes the use of the primary glucose range between 70 and 180 mg/dL. Occasionally, glucose values between 70 and 140 mg/dL can be used as a secondary range, especially for regulatory issues and comparability studies.

Time in tight range may be a more aspirational target for individuals without significant hypoglycemia risk who are seeking optimal glucose control. However, pursuing very tight control must be balanced against the increased risk of hypoglycemia and the potential for diabetes distress from overly intensive management.

Glucose Management Indicator

Bergenstal et al. used data coming from novel CGM studies associated to the previous ADAG results to develop a new index, the glucose management indicator (GMI). GMI is calculated from average CGM glucose values and provides an estimate of what A1C would be based on CGM data. This metric helps bridge the gap between traditional A1C testing and CGM-based management.

GMI is particularly useful for individuals who have conditions that affect A1C accuracy (such as anemia, hemoglobinopathies, or kidney disease) or who want more frequent estimates of their average glucose control without waiting three months between A1C tests. However, it’s important to remember that GMI is an estimate and may not perfectly match laboratory A1C values.

Artificial Intelligence and Predictive Analytics

The integration of artificial intelligence (AI) with CGM technology represents an exciting frontier in personalized diabetes management. CGM provides real-time and dynamic glucose monitoring, addressing the shortcomings of conventional methods, while AI enhances the clinical utility of CGM data through deep learning and advanced data analysis. This review examines the advantages of integrating CGM and AI from three perspectives: precise diagnosis, personalized intervention, and decision support.

AI algorithms can analyze patterns in CGM data to:

  • Predict future glucose levels and trends
  • Provide early warnings of impending hypoglycemia or hyperglycemia
  • Suggest optimal insulin doses based on current glucose, trends, and historical patterns
  • Identify subtle patterns that humans might miss
  • Personalize recommendations based on individual response patterns

These AI-enhanced capabilities are already being incorporated into advanced insulin pump systems and decision support tools, and will likely become increasingly sophisticated and widely available in the coming years.

Overcoming Barriers to CGM Use and Target Achievement

Despite the clear benefits of CGM technology for personalizing glucose targets and improving diabetes management, several barriers can prevent individuals from accessing or effectively using these devices.

Access and Affordability

Despite its benefits, challenges related to data security, affordability, and awareness of CGM devices remain. Cost can be a significant barrier, particularly for those without adequate insurance coverage. However, insurance coverage for CGM has been expanding, with many plans now covering CGM for individuals with type 1 diabetes and increasingly for those with type 2 diabetes who meet certain criteria.

With insurance coverage of CGMs improving and with Medicare covering CGMs for anyone who uses an insulin pump, injects insulin multiple times a day, or checks their blood glucose at least four times a day—there will likely be more and more people who begin to use them. Additionally, the FDA’s approval of over-the-counter CGM devices may improve accessibility for some individuals.

Education and Support

Simply having access to CGM technology is not enough—individuals need education and support to effectively interpret and act on the data. It is imperative that all CGM users should be trained in how to access, interpret, and answer questions regarding their glycemic control with accessible devices and tools. To make CGM data clinically meaningful for routine day-to-day diabetes management, clear guidance on CGM-derived glycemic targets should be provided to both PWDs and HCPs.

Comprehensive CGM education should include:

  • Device insertion, calibration (if required), and troubleshooting
  • Understanding CGM metrics and reports
  • Interpreting glucose trends and patterns
  • Making appropriate treatment adjustments based on CGM data
  • Setting and responding to alerts
  • Integrating CGM data with other aspects of diabetes management

Healthcare providers also need training to effectively use CGM data in clinical practice. This pilot program allowed PCPs to have a structured training experience with an endocrinologist with the goal of increasing familiarity and comfort with the integration of this technology into a primary care practice. As CGM becomes more widespread, ensuring that all healthcare providers who care for people with diabetes are comfortable interpreting and acting on CGM data will be essential.

Data Overload and Alert Fatigue

The wealth of data provided by CGM can sometimes feel overwhelming, and frequent alerts can lead to alert fatigue where individuals begin ignoring or disabling notifications. Strategies to address these challenges include:

  • Customizing alert settings to focus on the most important notifications
  • Using alert schedules that vary by time of day or activity
  • Focusing on key metrics rather than trying to analyze every data point
  • Reviewing data at regular intervals (daily, weekly) rather than constantly
  • Working with healthcare providers to develop clear action plans for different scenarios
  • Taking periodic breaks from intensive data review to prevent burnout

The goal is to use CGM data as a tool for empowerment rather than a source of stress or anxiety. Finding the right balance of engagement with the technology is an individual process that may require experimentation and adjustment over time.

Working with Your Healthcare Team

Personalizing glucose targets and optimizing CGM use is most effective when done in collaboration with a knowledgeable healthcare team. This team may include endocrinologists, primary care providers, diabetes educators, dietitians, and other specialists depending on individual needs.

Preparing for Appointments

To make the most of healthcare appointments when using CGM, individuals should:

  • Download and review CGM reports before appointments
  • Identify specific patterns or concerns to discuss
  • Bring questions about target setting and management strategies
  • Share information about lifestyle factors affecting glucose control
  • Be prepared to discuss quality of life and diabetes distress
  • Have realistic expectations about the pace of change and improvement

At the end of the day though, time in range data is meaningless unless both patients and their diabetes care team take the time to check it. Regular review and discussion of CGM data should be a standard part of diabetes care appointments.

Shared Decision-Making

The process of setting and adjusting glucose targets should involve shared decision-making between patients and providers. As for what time in range target you should aim for, remember: there’s no universal time in range goal. Yours will depend on your diabetes management needs and lifestyle, and your doctor can help you determine the right range for you.

Effective shared decision-making involves:

  • Clear communication about the benefits and risks of different target ranges
  • Consideration of individual preferences, values, and priorities
  • Discussion of the practical implications of different management strategies
  • Regular reassessment as circumstances change
  • Respect for patient autonomy while providing expert guidance

The goal is to arrive at targets and management strategies that are both medically appropriate and personally acceptable, maximizing the likelihood of long-term adherence and success.

The Future of Personalized Glucose Management

The field of continuous glucose monitoring and personalized diabetes management continues to evolve rapidly, with exciting developments on the horizon that promise to make glucose control even more precise and personalized.

Automated Insulin Delivery Systems

At its core, three interconnected elements—monitoring (enabling better glycemic control), alarm (providing real-time alerts), and motivation (facilitating personalized lifestyle modification)—drive CGM effectiveness. These extend to smart insulin pens (top) for connected insulin therapy, automated insulin delivery systems (left) for hybrid closed-loop glucose management, and digital therapeutics (right) for coaching and decision support to enhance clinical outcomes.

Automated insulin delivery (AID) systems, sometimes called “artificial pancreas” systems, integrate CGM with insulin pumps and sophisticated algorithms to automatically adjust insulin delivery based on glucose levels and trends. These systems are becoming increasingly advanced, with newer versions requiring less user input and achieving tighter glucose control with reduced hypoglycemia risk.

As these systems continue to improve, they will enable more individuals to safely achieve ambitious glucose targets that would be difficult or impossible to reach with manual insulin management. The algorithms can be personalized based on individual insulin sensitivity, carbohydrate ratios, and response patterns, providing truly individualized automated management.

Non-Invasive Monitoring Technologies

While current CGM systems require insertion of a sensor under the skin, research is ongoing into non-invasive glucose monitoring technologies that could measure glucose through the skin without any penetration. If successful, these technologies could further improve acceptance and use of continuous monitoring, particularly among those who are hesitant about sensor insertion.

Integration with Other Health Metrics

Without a doubt, CGM devices have revolutionized diabetes care and served as a pivotal step into the development of an artificial pancreas. The new frontier will be continuous monitoring of other human electrolytes like sodium, calcium, potassium or disease biomarkers like ketones that are already in regulatory approval stage.

Future systems may integrate glucose data with other continuously monitored health metrics such as heart rate, activity levels, sleep patterns, and stress markers to provide even more comprehensive insights into factors affecting glucose control. This holistic approach could enable more sophisticated personalization of targets and management strategies.

Expanded Applications Beyond Diabetes

The use of CGM and over-the-counter availability of CGM has the potential to detect and transform the care of conditions like prediabetes and sleep disorders, and helps to tailor and modify diet in people who can notice changes in glucose in real time with the use of these devices. As CGM becomes more accessible and affordable, its applications are expanding beyond traditional diabetes management to include prediabetes prevention, metabolic health optimization, and athletic performance enhancement.

This broader use of CGM technology will generate even more data about glucose patterns in diverse populations, potentially leading to more refined understanding of optimal glucose targets for different groups and circumstances.

Conclusion: Empowering Personalized Diabetes Management

Continuous glucose monitoring has fundamentally transformed diabetes management by providing the detailed, real-time data necessary to establish and achieve truly personalized glucose targets. Rather than relying on one-size-fits-all recommendations or limited snapshots from fingerstick testing, individuals with diabetes can now see the complete picture of their glucose control and make informed decisions about their management strategies.

The key to successful personalization lies in understanding that glucose targets should be individualized based on multiple factors including age, diabetes type and duration, presence of complications, hypoglycemia risk, activity level, and personal preferences. The standard time in range target of 70% (70-180 mg/dL) serves as a starting point, but the optimal target for any individual may be higher or lower depending on their specific circumstances.

CGM data provides the foundation for this personalization, revealing patterns and trends that guide adjustments to medication, nutrition, exercise, and other aspects of diabetes management. By analyzing metrics such as time in range, time above and below range, glucose variability, and the ambulatory glucose profile, individuals and their healthcare teams can identify opportunities for improvement and track progress toward goals.

Success with CGM-guided personalized management requires more than just technology—it demands education, support, collaboration with healthcare providers, and a balanced approach that optimizes glucose control while maintaining quality of life. The goal is not perfection, but rather sustainable improvement that reduces the risk of complications while allowing individuals to live full, active lives.

As CGM technology continues to advance, with improvements in accuracy, ease of use, integration with other devices and systems, and the incorporation of artificial intelligence, the ability to personalize glucose targets and management strategies will only improve. The future of diabetes care is increasingly personalized, data-driven, and patient-centered, with CGM serving as a cornerstone technology that empowers individuals to take control of their health.

For anyone living with diabetes, working with their healthcare team to establish personalized glucose targets based on CGM insights represents an opportunity to move beyond generic recommendations and achieve optimal control tailored to their unique needs, circumstances, and goals. The technology exists—the challenge now is ensuring that all who could benefit have access to it, along with the education and support needed to use it effectively.

To learn more about continuous glucose monitoring and personalized diabetes management, visit the American Diabetes Association, explore resources at the Endocrine Society, or consult with your healthcare provider about whether CGM might be appropriate for your diabetes management needs. Additional information about specific CGM devices and their features can be found through the FDA and manufacturer websites.